Introduction {#Sec1}
============

Extracellular vesicles (EVs) are membrane-surrounded vesicles released by numerous cell types into the extracellular microenvironment^[@CR1]--[@CR3]^. EVs are involved in cell--cell communication, coagulation, inflammation, immune response modulation, and disease progression^[@CR2],[@CR4]--[@CR7]^. Although EVs vary in size, biological function, and components, their significance in cancer progression and the potential use of EV molecules as novel cancer biomarkers has gradually increased. Cancer cells actively release EVs into neighboring tissues, and these EVs play dynamic roles in cancer progression and metastasis, invasion, angiogenesis, tumorigenesis, and immune modulation^[@CR8]--[@CR10]^. EVs released by cancer cells are usually chosen as a gateway in the search for biomarkers for a specific cancer type. Recent results pertaining to EV-cargo molecules, including proteins and miRNAs, are summarized in EVpedia (<http://evpedia.info>), an integrated and comprehensive database of EVs^[@CR11]^.

The main focus of this review is proteome profiling of EVs using mass spectrometry (MS)-based proteomic approaches. We discuss the mass spectral characterization of isolated EV proteins from different cancers and the use of these proteins as predictive cancer biomarkers. Additionally, we summarize the key characteristics of enriched proteins in cancer-associated EVs as potential therapeutic targets and provide novel information on their roles in cancer development and progression. Information provided in this review may help in understanding recent progress regarding EV biology and the prospective roles of EVs as new noninvasive biomarkers and therapeutic targets, as well as emerging therapeutic opportunities and associated challenges.

Classification of EVs {#Sec2}
=====================

EVs are small spherical vesicles that are secreted into the extracellular milieu by many cell types. The term "EV" was invented by the International Society of Extracellular Vesicles (ISEV) and is used to define all phospholipid bilayer-bound vesicles that are secreted by cells into the extracellular microenvironment, regardless of the differences in biogenesis, size, and composition^[@CR12],[@CR13]^. The roles of EVs in different physiological and pathological processes have made them a novel field of research. EVs are categorized into several subtypes based on their size, density, shape, subcellular origin, function, and molecular cargo^[@CR14]^. The four major subtypes of EVs are exosomes, microvesicles, apoptotic bodies, and oncosomes (Table [1](#Tab1){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"}). Exosomes are 30--200-nm-sized homogeneous membrane vesicles, and they form through the endosomal trafficking pathway^[@CR5],[@CR15],[@CR16]^. Exosomes contain late endosomal markers, even though biochemically indistinguishable vesicles can bud directly from the plasma membrane^[@CR16],[@CR17]^. They play critical roles in cell--cell communications, such as that occurring during the regulation of cell and tissue homeostasis, as well as in pathological conditions^[@CR18]^. Microvesicles are 100--1000-nm-sized heterogeneous membrane vesicles that originate via outward budding and the fission of the plasma membrane due to dynamic interactions during phospholipid redistribution. Phospholipid distribution is controlled by aminophospholipid translocases^[@CR16],[@CR18]--[@CR24]^ and cytoskeletal protein contraction. Microvesicles are released mostly under cellular stress or in pathological processes^[@CR18]^. Like exosomes, microvesicles transfer bioactive molecules into target cells. Apoptotic bodies (\> 1 µm) are released by cells that undergo the apoptosis process or programmed cell death^[@CR18],[@CR24]^, and they can be characterized by cellular organelles and DNA. Finally, the vesicles named "oncosomes" are much larger than most other EV types characterized to date (1--10 μm). Owing to their unusual size, large oncosomes might have unique properties in vivo and would provide novel opportunities for tumor profiling^[@CR25]^.Table 1Brief classification of extracellular vesiclesEV subtypeDiameterBiogenesisMarkersReferencesExosomes30--200 nmReleased from multivesicular bodies within the endosomal networkMembrane transport and fusion proteins (annexins, GTPases, and flotillin), tetraspanins (CD9, CD63, CD81, and CD82), heat-shock proteins (Hsc70 and Hsp90), proteins involved in MVB biogenesis (Alix and Tsg101), lipid-related proteins and phospholipases, ESCRT, and MHC^[@CR4],\ [@CR5],\ [@CR13]--\ [@CR15]^Microvesicles100--1000 nmProduced by direct budding from the cell membraneSelectins, integrins (B1), metalloprotease surface phosphatidylserine, vesicle-associated membrane protein 3, CD34, CD40, CD45, glycophorin, or blood group antigens^[@CR16]--\ [@CR22],\ [@CR25],\ [@CR58]^Apoptotic bodies\>1 µmReleased only by cells undergoing apoptosis or programmed cell death (apoptosis fragments)Surface phosphatidylserinehistones, calnexin, cytochrome C, annexin V, C3b, and TSP^[@CR4],\ [@CR14]--\ [@CR22]^Oncosomes1--10 µmNon-apoptotic plasma membrane blebs shed by "ameboid" migrating tumor cells or from tumorsCav-1, ARF6, Myr, Akt1, and HB‑EGF^[@CR23]^Fig. 1Biogenesis of four major subtypes of extracellular vesicles

EVs contain proteins, lipids, metabolites, and RNAs. However, the mechanisms by which these components enter EVs remain obscure. EVs are shed from almost all cell types and are present in biological fluids and conditioned cell culture media. EVs are involved in cell--cell communication, coagulation, inflammation, immune response modulation, and disease progression^[@CR4]--[@CR7]^. The functional roles of EVs in intercellular communication have made them of major interest in many scientific fields. The biomolecular composition of EVs could play a significant role in disease progression in several neurodegenerative diseases as well as in cancer.

MS in EV proteome analyses {#Sec3}
==========================

EV proteome analysis is a novel approach and is part of the growing interest in proteomics cancer research. Over the past three decades, many proteomics studies performed on EVs have elucidated their diverse roles. Large-scale proteomics datasets and protein-interaction networks have established significant relationships between EV proteins, which improves the understanding of vesicle biogenesis and pathophysiological roles^[@CR24],[@CR26],[@CR27]^. Proteomic studies on EVs from different origins have also suggested a controlled protein-sorting mechanism and the random packaging of EV proteins from various cell types that contain common vesicular proteins. Furthermore, proteomic studies of EVs have produced a high-throughput vesicular proteome dataset from various cell types and body fluids^[@CR28]^. Since EVs are normally isolated in small amounts, better sensitivity is required for their analysis. Liquid chromatography (nanoscale or ultra-high performance)--electrospray ionization tandem mass spectrometry (LC/ESI--MS/MS) is the most popular and versatile analytical technique to study the molecular contents of EVs. In particular, nano-ESI--MS/MS provides high sensitivity and resolution, allowing the detection, identification, characterization, and quantification of thousands of proteins from even a single EV sample. Similar to other biological fields, LC--MS/MS-based technological platforms have become the most popular fundamental tools for elucidating the structural and functional architecture of EVs. The fragment ions from ESI (positive- and negative-ion) tandem MS experiments provide the composition, unambiguous structural characterization, and proper identification of proteins present in various biological samples. Due to the high sensitivity and small initial sample volumes required for MS, MS-based proteomic analysis has increased the understanding of EV protein content. Several investigators^[@CR26],[@CR29]--[@CR32]^ have used ESI tandem MS experiments in combination with chromatographic methods (HPLC, UHPLC, UPLC, and nano LC) to profile and structurally characterize proteins in various cancer cells, tissues, biofluids, and biological samples, which have been summarized in Table [2](#Tab2){ref-type="table"}.Table 2Summary of biomarker candidate proteins in extracellular vesicles from different cancersCancer typeCancer-specific EV proteinsIsolation of EVsCharacterizationSample sourceReferencesBladder cancerEDIL-3UCWB, TEMTCC, T24, SV-HUC, and urineBeckham et al.^[@CR59]^UCTEM, NTATCCSUP, T24, UMUC3, RT3 SVHUC, and urineSilvers et al.^[@CR60]^ITGB1, ITGA6, CD36, CD44, CD73, CD10, MUC1, BSG, and 5T4UCNTA, TEM, and WBHT1376, urineWelton et al.^[@CR34]^UCNTA, TEM, and WBT24, FL3, and SLT4Jeppesen et al.^[@CR61]^Colon cancerHGSExoQuickNTA, TEM, and WBHCT116Sun et al.^[@CR62]^Clstn1, VCP, and RuVB-like1 (O-GlcNAcylation)UCTEM, WBCCD841, HT29, SW480, and SW620Chaiyawat et al.^[@CR63]^F2BDGNTA, TEM, and WBSW480, SW620Schillaci et al.^[@CR64]^YWHAZUCHCT116, patient colon tumorHillary et al.^[@CR65]^ACACAUCCitrus-limon, SW480Raimondo et al.^[@CR66]^UCNTA, WBSW620Guo et al.^[@CR67]^EPCAM-CLDN7 and TNIK-RAP2ABDGNTA, TEM, and WBSW480, SW620Ji et al.^[@CR53]^BDGNTA, TEM, and WBPatient tumorChoi et al.^[@CR26]^BDGNTA, TEM, and WBHT-29Choi et al.^[@CR27]^GPA33, CDH17, CEA, EpCAM, PCNA, EGFR, MUC13, MINK1, KRT18, MAPK4, CLDN (1, 3, and 7), CEP55, EFNB1, and EFNB2TEM, WBLIM1215 cells, urine, mast and cellsSuresh et al.^[@CR33]^UCNTA, TEM, and WBDks-8, DLD-1, and DKO-1Demory et al.^[@CR68]^BDGNTA, TEM, and WBSW480, SW620Choi et al.^[@CR69]^DKK4 and DNMT3AUCTEM, WBSW480, SW480APCLim et al.^[@CR70]^MAC2BP, ALIX, 14--3--3 isoforms, PFN1, CALU, and IL-8UCTEMLIM1215 cellsJi et al.^[@CR71]^Prostate cancerUCDLS, TEMpc3-HSP27, HEK-293Rauschenberger et al.^[@CR72]^UCPC3, DU145, VCaP, LNCaP, C4--2, and RWPE-1Hosseini-Beheshti et al.^[@CR73]^THBS1, GSN, and ITGB1UCWBLNCaPSoekmadji et al.^[@CR74]^ITGB4 and VCLUC, CD9 antibody magnetic beadsNTA, WB, and TEMPC-3Kawakami et al.^[@CR75]^CD9UCTEM, WBLNCaP, DUCaP PCa cells, and plasmaSoekmadji et al.^[@CR76]^UCTEM, WB, and NTADU145 Tax-Sen, DU145 Tax-ResKharaziha et al.^[@CR77]^CD151 and CDCP1UCPC-3Sandvig et al.^[@CR78]^PDCD6IP, FASN, XPO1, and ENO1UC, SGTEM, WBPNT2C2, RWPE1, PC346C, and VCaPDuijvesz et al.^[@CR30]^UCOsteoblastsBilen et al.^[@CR79]^Lung cancerAKT and ERK1/2UCWBH3255, H1650Van et al.^[@CR80]^AKT1, GSK3B, EIF4E, MTOR, RELA, and RASBDGTEM, WBPC9, PC9RChoi et al.^[@CR81]^ALLIX, TSG101, CD3, EGFR, SRC, KRAS, and NRP1PEG precipitation, UC, and BDGTEM, WBA54, HCC827, and HBECClark et al.^[@CR39]^P53 and EGFRqEVTRPS, TEM, and WB30KTp53/EGFRLobb et al.^[@CR82]^HCCExoQuickTEM, WBHep3B, 97 H, and LM3Zhang et al.^[@CR83]^RRAS, CD44, CDC42, and CLND3UCWBHKCI-C3, HKCI-8, MHCC97L and MIHAHe et al.^[@CR84]^UCNTA, TEM, and WBHepG2Wang et al.^[@CR43]^UCWB, EMHuh7.5.1 Huh7-ETRamakrishnaiah et al.^[@CR85]^Breast cancerUCTEMPlasma, bone metastasis explant-conditioned media, and pleural effusionTucker et al.^[@CR86]^vn96 affinity capture of EVWB and TEMSKBR3, MCF-7, and MCF-10aGriffiths et al.^[@CR87]^Free-flow electrophoresisSKBR3 (hypoxia, normoxia)Thomas et al.^[@CR88]^UCTEM, WB, and NTAMCF-7, MDA-MB-231Harris et al.^[@CR32]^DEL-1Plasma, MDA-MB-231Moon et al.^[@CR89]^EDIL3BDGNTA, TEM, and WBMCF-7, MDA-MB-231Lee et al.^[@CR29]^IL-6, TNFa, GCSF, and CCL2UCTEM, WB, and FCMCF10A, MDA-MB-231, and MCF7Chow et al.^[@CR90]^POSTNUC, SGNTA, TEM, and WBMCF7, MDA-MB-231, 67NR, 4T1, and plasmaVardaki et al.^[@CR91]^UCTEM, WB, and NTAcal51 TNBCKavanagh et al.^[@CR92]^UCTEM, WBMDA-MB-231 cellsPalazzolo et al.^[@CR37]^MTDH and CPUCTEM, WB, and NTA4T1, 4T1.2, 67NR, and 66cl4Gangoda et al.^[@CR93]^UCTEM, DLS, and WBVCaPDomenyuk et al.^[@CR94]^Ovarian cancerUCTEM, WBOVCAR3, OVCAR433, OVCAR5, and SKOV3Sinha et al.^[@CR95]^UCWB, TEMSKOV3, OVMEscrevente et al.^[@CR96]^G6PD and TKTUCWB, TEMOVCA429, HO8910PMYi et al.^[@CR97]^UCTEM, WBOVCAR-3, IGROV1Liang et al.^[@CR41]^UCTEM, WBSKOV3, CAOV3, and HUVECYi et al.^[@CR98]^Pancreatic cancerEGFRUCWBBxPC3, MiaPaca2, and Panc1Adamczyk et al.^[@CR99]^ZIP4SBI ExoQuick‐TC KitTEM, WBPC‐1.0 (highly malignant), PC‐1 (moderately malignant)Jin et al.^[@CR100]^CEACAMs and ECM proteinsUCTEMPancreatic duct fluidZheng et al.^[@CR101]^UC, SGEMSOJ-6, BxPC-3, MiaPaCa-2, and Panc-1Ristorcelli et al.^[@CR36]^MYOFUCDLS, TEM, and WBMDA-MB-231, MDA-MB-468, BT-549, Hs 578 T, MCF7, MCF-10A, ZR-75--1, BT-474, SK-BR-3, and CFPAC-1Blomme et al.^[@CR102]^BDGTEM, WBPanc1, BxPc3, MiaPaca2, and HPSCKlein-Scory et al.^[@CR103]^MIFUCNTAPKCY, PAN02Costa-Silva et al.^[@CR31]^UC, SGTEM, WBPanc02, Panc02-H7 cellsYu et al.^[@CR104]^CLDN4, EPCAM, CD151, LGALS3BP, HIST2H2BE, and HIST2H2BFUCWB13 human PDAC, 2 non-neoplastic cell linesCastillo et al.^[@CR105]^PLECUC, ExoQuick-TCDLS, TEM, and WBPDAC, C6 glioma cells, and HPDEShin et al.^[@CR106]^WNT5BBDG, SGEMCHO, Caco-2 cellsHarada et al.^[@CR46]^CCAUCTEM, WBHuman bile, H69 cell lineChaiyadet et al.^[@CR107]^S100A6, LUM, LCP1, YWHAZ, and VIMUCTEMHamster liver tissue, KKU055Khoontawad et al.^[@CR108]^UCTEM, WBKKU-100, KKU-M213, and H69Dutta et al.^[@CR42]^Blood cancerMARCKSUC, SGCM, FACSK562, LAMA84Taverna et al.^[@CR109]^VCPUCTEMU937, Mec1Bosque et al.^[@CR56]^UCWB, FCPrimary CLL cellsPaggetti et al.^[@CR110]^DNMT1 and HELLSUCNTA, FCMolm-14, HL-60, and OP9 cellsHuan et al.^[@CR111]^MHC-1, MHC-2, HSC70, HSP90, and ICMA-1UCTEM, WBRaji cellsYao et al.^[@CR40]^Oral cancerExoQuickNTA, TEMHUVEC, SCC15Andrade et al.^[@CR112]^NAP1UltrafiltrationNTA, TEM, WB, and CMCAL 27, SCC-25Wang et al.^[@CR44]^HSP90UCTEM, NTAHSC-3, HSC-3-M3Ono et al.^[@CR113]^*WB* western blotting, *TEM* transmission electron microscopy, *NTA* nanoparticle tracking analysis, *DLS* dynamic light scattering, *TRPS* tunable resistive pulse sensing, *FC* flow cytometry, *CM* confocal microscopy

EV proteomes in various cancers and biomarker discovery {#Sec4}
=======================================================

Proteomic analysis of EVs has revealed significant changes in protein expression under various physiological and pathological conditions^[@CR26],[@CR29],[@CR30]^. Characterization of these proteomic profiles may be useful in understanding disease pathogenesis and assisting in the discovery of new biomarkers for different diseases. The secretion of EVs from several types of tumor cells is a significant means of conditioning and altering the tumor microenvironment by malignant cells^[@CR31],[@CR32]^. Multiple studies have reported that the secretion of EVs from cancer cells contributes to angiogenesis, metastasis, tumor formation, and disease progression^[@CR2],[@CR10],[@CR31],[@CR32]^. EVs are more attractive sources of biomarkers because of their biological consequences and relatively noninvasive accessibility in a wide range of biological fluids. EVs have been studied in relation to numerous cancers, such as colorectal^[@CR27],[@CR33]^, bladder^[@CR34]^, prostate^[@CR35]^, pancreatic^[@CR36]^, breast^[@CR37]^, gastric^[@CR38]^, lung^[@CR39]^, blood^[@CR40]^, ovarian^[@CR41]^, cholangiocarcinoma^[@CR42]^, hepatocellular carcinoma^[@CR43]^, and oral squamous cell carcinoma^[@CR44]^ (Table [2](#Tab2){ref-type="table"}), as well as cardiovascular diseases^[@CR45]^ and malignancies of the central nervous system^[@CR21]^. The proteomic analysis of EVs, specifically the analysis of their protein composition, may be helpful for further understanding the mechanisms of their biogenesis and their functional roles. Molecular communication between cancer cells and their stromal microenvironment is a key factor for cancer progression^[@CR46],[@CR47]^. In conjunction with typical secretory pathways, it was proposed that these small membranous vesicles are alternate mediators of intercellular communication^[@CR19]^. EVs carry an effector-rich proteome with the ability to control different functional properties of the recipient cell^[@CR48]^. The protein composition of EVs from different sources was studied previously by using MS^[@CR30],[@CR49]--[@CR54]^, providing a robust basis for the identification of biomarker proteins in EVs for the purpose of quality control research. A thorough understanding of the protein composition of EV subtypes and the extent to which EV composition reflects the source cell composition is essential for further development of diagnostics and therapeutics. Although EVs are secreted by almost all cell types, some available data suggest the enhanced release of EVs under pathological conditions, such as cancer^[@CR55]^. It is reasonable to expect that these vesicles may also play key roles in tumorigenesis since they can facilitate distant intercellular communication. Tumor-derived EVs typically carry tumor antigens, and functional proteins can be transferred to recipient cells through EVs^[@CR23],[@CR54],[@CR56]^. A better understanding of the molecular bases underlying cancer invasion and metastasis is necessary to develop effective targets for therapy.

EV proteins from many cancers have similar biological processes and functions. To understand the functions of differentially expressed proteins (DEPs) in cancer, we performed gene ontology analysis on a variety of DEPs^[@CR57]^. As expected, the EV--DEPs from different cancer types were implicated in similar biological processes, such as cell adhesion, migration, and transport. Considering that EVs are potential metastasis factors, those proteins appear to be relevant for cancer metastasis or cancer cell proliferation. Of the 12 different cancers evaluated, we observed that DEPs that overlapped more than five times were primarily related to cancer metastasis or cancer cell proliferation, and many of the DEPs had strong interactions with each other (Fig. [2](#Fig2){ref-type="fig"}). Even though the selection of these DEPs from different cancers was biased, the roles of EVs in different cancers focused mainly on cell adhesion and cell migration.Fig. 2Protein--protein interaction network of differentially expressed extracellular vesicle proteins in cancer cell-derived EVs

Conclusions {#Sec5}
===========

In this review, we summarized different EV studies to discuss the potential of EVs in cancer treatment. All studies discussed in this review indicated that the specific protein composition of various EVs has high potential for identifying different cancers. The majority of these studies revealed the relationship of cancer with changes in the protein contents of various body fluids. Moreover, we have highlighted the emerging roles of EVs in cancer, specifically their role in metastasis, which opens the possibility of the rapid translation of EV research for clinical applications in diagnosis, prognosis, and treatment. Ultimately, the majority of the investigations discussed in this review need further verification in large-cohort, multicenter clinical studies. In the future, highly reliable EV proteome data could be combined with well-developed current popular genomic and other "omics-" studies to provide extended knowledge of EVs from the perspective of systems biology approaches.

Future perspectives {#Sec6}
===================

There are many perspectives on the potential contribution of EV research for the development of cancer therapeutics and diagnosis. EVs could play key roles in intercellular communication during cancer development, which may offer new therapeutic strategies for various cancers. EV protein composition in different body fluids reveals the overall condition of the patient and is also useful for screening the efficacy and toxicity of anticancer treatments. Additionally, EVs could be used as cancer vaccines and drug delivery components. Moreover, the inhibition of intercellular communication through EVs might provide opportunities to suppress tumor progression. In the near future, clinical applications of EVs could contribute to cancer management and treatment. However, before EV-targeted therapy can be applied in cancer, the identification of cancer-specific genes or molecules that are crucial for EV communication is necessary.
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